Innoviva Reports First Quarter 2022 Financial Results
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021.
Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023.
Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader.
Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader.
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022.
Gross royalty revenue
